Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy

INTRODUCTION: Targeted therapies for aggressive breast cancers like triple negative breast cancer (TNBC) are needed. The use of small interfering RNAs (siRNAs) to disable expression of survival genes provides a tool for killing these cancer cells. Cyclin dependent kinase 11 (CDK11) is a survival pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kren, Betsy T, Unger, Gretchen M, Abedin, Md J, Vogel, Rachel I, Henzler, Christine M, Ahmed, Khalil, Trembley, Janeen H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344788/
https://www.ncbi.nlm.nih.gov/pubmed/25837326
http://dx.doi.org/10.1186/s13058-015-0524-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344788/
https://www.ncbi.nlm.nih.gov/pubmed/25837326
http://dx.doi.org/10.1186/s13058-015-0524-0

Ejemplares similares